Background Napabucasin is a first-in-class cancer stemness inhibitor that targets STAT3,
which is a poor prognostic factor in colorectal cancer. This study aimed to test napabucasin in …

MicroRNAs (miRs) are short non-coding RNAs that bind complementary sequences in mRNA
resulting in translation repression and/or mRNA degradation. We investigated expression …

… Conflict-of-interest statement: Michael N Rosen and Michael M Vickers declare no conflict
of interest for this topic. Rachel A Goodwin has received compensation for an advisory role …

Background Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) for
rectal cancer is associated with better long-term outcomes, and is used as an early indicator …

Background The outcomes and prognosis of patients with brain metastases from advanced
renal cell carcinoma (RCC) are not well characterized in the targeted-therapy era. Methods …

Background A standard therapy for locally advanced rectal cancer (LARC) includes
fluoropyrimidine (FP)-based neoadjuvant chemoradiation (nCRT). Previous studies have …

Background Self-expanding metal stents (SEMS) are increasingly used in the treatment of
malignant large bowel obstruction in the setting of inoperable colorectal cancer. Perforation is …

OBJECTIVES: To characterize and evaluate the efficacy of second-line therapy in patients
who had progressed on initial anti-vascular endothelial growth factor (VEGF) therapy. …

Background The PROSPECT trial (N1048) is evaluating the selective use of chemoradiation
in patients with cT2N1 and cT3N0-1 rectal cancer undergoing sphincter-sparing low …

Before the advent of molecular targeted therapy, treatment of metastatic renal cell carcinoma
(mRCC) involved immunotherapy with high-dose interleukin (IL)-2 in selected patients, …